Men with high-risk PCa (HRPCa) characterized by aggressive pathological grade, advanced T stage, or a high level of prostate-specific antigen (PSA) were at a higher risk of treatment failure, oncological progression, and local or systematic recurrence (Chang et al., 2014; Wilkins et al., 2020). The gene discussed is KLK3; the disease is posterior cortical atrophy.